3,4-Dihydroxyxanthone

3,4-Dihydroxyxanthone

SCHEMBL133422

O=c1c2ccccc2oc2c(O)c(O)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 1.00
ATP1A1 P05023 3/20 0.70
ATP1B1 P05026 3/20 0.70
ATP1A3 P13637 3/20 0.70
ATP1B2 P14415 3/20 0.70
ATP1A2 P50993 3/20 0.70
ATP1B3 P54709 3/20 0.70
FXYD2 P54710 3/20 0.70
ATP1A4 Q13733 3/20 0.70
NUDT1 P36639 1/20 0.70
MAOA P21397 9/20 0.70
ACE P12821 2/20 0.66
KDM5A P29375 1/20 0.63
KDM4E B2RXH2 2/20 0.57
MAPT P10636 2/20 0.57
ALDH1A1 P00352 1/20 0.57
GLA P06280 1/20 0.57
CYP3A4 P08684 1/20 0.57
HPGD P15428 1/20 0.57
PGAM1 P18669 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
3,4-Dihydroxyxanthone SCHEMBL30668688 1.00 PTGS2 (1.00) PTGS2ATP1A1ATP1B1ATP1A3ATP1B2
Xanthone SCHEMBL3616855 0.87 PTGS2 (0.76) PTGS2ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL3881176 0.85 PTGS2 (0.74) PTGS2ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL24120562 0.83 PTGS2 (0.71) PTGS2MAOAKDM5AKDM4EMAPT
SCHEMBL9835933 0.83 PTGS2 (0.71) PTGS2MAOAKDM5AKDM4EMAPT
SCHEMBL9836624 0.83 PTGS2 (0.71) PTGS2MAOAKDM5AKDM4EMAPT
SCHEMBL1444851 0.83 ATP1A1 (1.00) PTGS2ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL30451609 0.83 ATP1A1 (1.00) PTGS2ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL1788224 0.82 MAOA (1.00) PTGS2ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL149545 0.81 MAOA (0.73) PTGS2ATP1A1ATP1B1ATP1A3ATP1B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030891-B2 Xanthonic compounds and their use as antifouling agents CIIMAR—CENTRO INTERDISCIPLINAR DE INVESTIGACAO MARINHA E AMBIENTAL (PT) 2024-07-09 US claimed
CN-113226035-B Xanthene compounds and their use as antifouling agents 海洋与环境研究交叉学科中心 2023-10-31 CN claimed
US-20210395264-A1 XANTHONIC COMPOUNDS AND THEIR USE AS ANTIFOULING AGENTS FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA (PT) 2021-12-23 US claimed
CN-113226035-A Xanthene compounds and their use as antifouling agents 海洋与环境研究交叉学科中心 2021-08-06 CN claimed
CN-107445970-B DMXAA-pyraloxanthone hybrid compound and preparation method and application thereof 广州药本君安医药科技股份有限公司 2020-02-07 CN claimed
US-20150272923-A1 Na/K-ATPase Ligands, Ouabain Antagonists, Assays and Uses Thereof THE UNIVERSITY OF TOLEDO (US) 2015-10-01 US claimed
US-20140031419-A1 Na/K-ATPase Ligands, Ouabain Antagonists, Assays and Uses Thereof THE UNIVERSITY OF TOLEDO (US) 2014-01-30 US claimed
US-20100137421-A1 SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE 2010-06-03 US claimed
WO-2008057604-A9 SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE UNIV CALIFORNIA (US) 2008-10-02 WO claimed
WO-2008057604-A2 SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-05-15 WO claimed
US-5741813-A ADMINISTERING SUBSTITUTED XANTHONES NATIONAL SCIENCE COUNCIL (TW) 1998-04-21 US claimed
US-12030891-B2 Xanthonic compounds and their use as antifouling agents CIIMAR—CENTRO INTERDISCIPLINAR DE INVESTIGACAO MARINHA E AMBIENTAL (PT) 2024-07-09 US disclosed
CN-113226035-B Xanthene compounds and their use as antifouling agents 海洋与环境研究交叉学科中心 2023-10-31 CN disclosed
US-20210395264-A1 XANTHONIC COMPOUNDS AND THEIR USE AS ANTIFOULING AGENTS FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA (PT) 2021-12-23 US disclosed
US-20210395264-A1 XANTHONIC COMPOUNDS AND THEIR USE AS ANTIFOULING AGENTS FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA (PT) 2021-12-23 US disclosed
EP-1620564-A2 METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS Cytovia, Inc. (US) 2006-02-01 EP disclosed
US-20050004026-A1 Methods of treating diseases responsive to induction of Apoptosis and screening assays CYTOVIA, INC. 2005-01-06 US disclosed
WO-2004094647-A2 METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS CYTOVIA, INC. (US) 2004-11-04 WO disclosed
US-5741813-A ADMINISTERING SUBSTITUTED XANTHONES NATIONAL SCIENCE COUNCIL (TW) 1998-04-21 US disclosed
US-5495005-A ANTICOAGULANTS, CARDIOVASCULAR DISORDERS NATIONAL SCIENCE COUNCIL (TW) 1996-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137421-A1 SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE BAD, CASP3, BID PTGS2 855/4885ATP1A1 4675/4885ATP1B1 4425/4885
US-20050004026-A1 Methods of treating diseases responsive to induction of Apoptosis and screening assays HEATR6, HEATR1, AIP PTGS2 2093/4885ATP1A1 2281/4885ATP1B1 2555/4885
US-20150272923-A1 Na/K-ATPase Ligands, Ouabain Antagonists, Assays and Uses Thereof ATP1A2, ATP1B1, ATP1A1 PTGS2 3533/4885ATP1A1 3/4885ATP1B1 2/4885
US-20140031419-A1 Na/K-ATPase Ligands, Ouabain Antagonists, Assays and Uses Thereof ATP1A2, ATP1B1, ATP1A1 PTGS2 3533/4885ATP1A1 3/4885ATP1B1 2/4885
US-20210395264-A1 XANTHONIC COMPOUNDS AND THEIR USE AS ANTIFOULING AGENTS PGLS, Q6ZSR9, ALG1 PTGS2 3074/4885ATP1A1 3994/4885ATP1B1 3493/4885
US-12030891-B2 Xanthonic compounds and their use as antifouling agents PGLS, Q6ZSR9, ALG1 PTGS2 3074/4885ATP1A1 3994/4885ATP1B1 3493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.